Eli Lilly has struck a deal to buy Crispr gene-editing start-up Verve Therapeutics for up to $1.3bn, the latest acquisition ...

The clinical-stage biotech is developing gene-editing CRISPR technology. Editas has reported encouraging testing results in ...

Scientific breakthroughs have had life-changing effects on our nation's health and economy. Now is not the time to slash ...

Baker Brothers’ Q1 2025 portfolio reveals biotech investment trends. See more on their top holdings, stake changes, and ...

For his DC-PGE project (DNA-binding domain Conditioned Precision Genome Editing), Prof. Frank Buchholz has been awarded an Advanced Grant from the European Research Council (ERC), the highest endowed ...

One way would be to ensure there is a consistent and predictable yield year by year. For two years in a row, beginning in the ...

This video combines entertainment and learning by showcasing the art of ball control through engaging juggling routines. With creative techniques and insightful demonstrations, it delivers both fun ...

There may be hopeful news ahead for families with a history of breast and ovarian cancer. Researchers from the University of ...

Eli Lilly & Co. aims to offer a one-and-done heart-disease medicine by paying up to $1.3 billion for Verve Therapeutics Inc., the maker of a new gene-editing treatment, Lilly said on Tuesday.

As Africa reckons with shrinking foreign research support and looming health threats, scientists across the continent are pushing for a more self-reliant future.